Concepedia

In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study

Francesco Pepe, Elena Guerini‐Rocco, Matteo Fassan, Nicola Fusco, Davide Vacirca, Alberto Ranghiero, Konstantinos Venetis, Alessandra Rappa, Sergio Vincenzo Taormina, Gianluca Russo,

Journal of Clinical Pathology · 2023 · 23 citations · 24 references

DOIFull text

Open access

Abstract

In-house testing for HRD can be reliably performed with commercially available next-generation sequencing assays.

References

24

Cancer statistics, 2019

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 20.7K citations · Full text

, , +19

Integrated genomic analyses of ovarian carcinoma

Debra Bell, Andrew Berchuck, Wendy Winckler · Nature · 2011 · 8K citations · Full text

, , +3

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

, , +10